The upcoming presentation at the Bellagio, led by co-principal investigator Prof. Dr. Stefano Barco, highlights a critical segment of the original 1,252-patient cohort. While the primary SirPAD results—published in the New England Journal of Medicine—confirmed that Concept Medical’s MagicTouch sirolimus-coated balloon significantly reduces major adverse limb events compared to uncoated alternatives, this subgroup data addresses the distinct quality-of-life requirements for those suffering from intermittent claudication without tissue loss.

As the medical community gathers for the late-breaking clinical trial program, the findings will clarify whether the durability of sirolimus-based intervention translates into sustained functional improvement for this population. By narrowing the scope to femoropopliteal disease, the researchers aim to refine endovascular therapy standards where the primary clinical goal shifts from preventing amputation to maintaining active mobility.